{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T06:31:29Z","timestamp":1698474689359},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,2,8]],"date-time":"2006-02-08T00:00:00Z","timestamp":1139356800000},"content-version":"vor","delay-in-days":4817,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[1992,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Obtaining and sustaining an erection are common problems for the male spinal cord injury patient. Intracavernous injection of vasoactive substances offers a new treatment option but it must be approached with caution in this population. In this work, the use of an alpha\u2010adrenergic blocking agent, moxisylyte, after intracavernous administration for complete paraplegic patients with erectile impotence is described. During this study, the pharmacokinetic profile of moxisylyte has been defined. Unchanged moxisylyte is not found in plasma, this drug is immediately metabolized after administration. Three metabolites were found in plasma: desacetylmoxisylyte (DAM), conjugated DAM, and conjugates of desmethylated DAM (MDAM). Maximum plasma levels of 72\u00b73 ng ml<jats:sup>\u22121<\/jats:sup>, 301\u00b74 ng ml<jats:sup>\u22121<\/jats:sup>, and 88\u00b78 ng ml<jats:sup>\u22121<\/jats:sup> are obtained 0\u00b722 h, 0\u00b79 h, and 2\u00b708 h after drug administration for these three metabolites, respectively. The elimination half\u2010lives are 0\u00b789 h, 2\u00b716 h, and 5\u00b732 h and the MRT, 1\u00b738 h, 3\u00b723 h, and 8\u00b745 h, respectively. No side\u2010effects were noted, only one patient presented sleepiness. Successful erections (10 to 25 min) were obtained in all patients and no priapism was noted.<\/jats:p>","DOI":"10.1002\/bdd.2510130905","type":"journal-article","created":{"date-parts":[[2006,10,14]],"date-time":"2006-10-14T13:16:05Z","timestamp":1160831765000},"page":"671-679","source":"Crossref","is-referenced-by-count":8,"title":["Moxisylyte plasma kinetics in humans after intracavernous administration"],"prefix":"10.1002","volume":"13","author":[{"given":"Pierre","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Bressolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Mosser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Navratil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Galtier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1965.tb07701.x"},{"key":"e_1_2_1_3_2","first-page":"1221","article-title":"Die Behandlung der hypertensive Spattoxikosc mit opilon","volume":"15","author":"Mosler W.","year":"1960","journal-title":"Dte Gesundh Wes."},{"key":"e_1_2_1_4_2","first-page":"1751","article-title":"Erfahrungen Uber die behandlung von Kopftraumen mit Opilon Medsche","volume":"56","author":"Aleksic K.","year":"1961","journal-title":"Kiln."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/2.4.360"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127006900900406"},{"key":"e_1_2_1_7_2","first-page":"1183","article-title":"Von Klinish pharmakologisher Nachweis der Wirkung von essigs\u00e4ure\u2010[4\u2010(2\u2010demethyl\u2010aminoaethoxy)\u20105\u2010isopropyl\u20102\u2010methyl\u2010phenyl]\u2010ester\u2010HCl (Moxisylyt)","volume":"21","author":"Wasilewski A.","year":"1971","journal-title":"Arzneimittelforsch (Drug Res.)"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5898.90"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007997709115288"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189699"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189708"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.143.4.332"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)43130-2"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90910-2"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0022-5347(17)40206-0","article-title":"Papaverine hydrochloride in peripheral blood and the degree of penile erection","volume":"143","author":"Tanaka T.","year":"1990","journal-title":"J. Urol."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42060-X"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)41309-7"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)81096-8"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189743"},{"key":"e_1_2_1_20_2","first-page":"507","volume-title":"Proceedings of the 7th International Congress of Medical Informatics Europae","author":"Gomeni C.","year":"1987"},{"key":"e_1_2_1_21_2","first-page":"1","article-title":"Le temps de pr\u00e9sence moyen dans l'organisme: un nouveau param\u00e8tre pharmacocin\u00e9tique","volume":"41","author":"Taburet A. M.","year":"1986","journal-title":"Th\u00e9rapie"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(89)90194-X"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1980.tb02018.x"},{"key":"e_1_2_1_24_2","unstructured":"P.Costa M. F.Bressolle Bromet\u2010Petit J. MosserandB.Sarrazin Pharmacokinetic of moxisylyte in healthy volunteers after intravenous and oral administrations: Bioequivalence study of two formulations.J. Pharm. Sci. in press."},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912143212406"},{"key":"e_1_2_1_26_2","first-page":"S2","article-title":"Systemic pharmacokinetics of papaverine and phentolamine: comparison of intravenous and intracavernous application","volume":"2","author":"Hakenberg O.","year":"1990","journal-title":"Int. J. Impotence Res."}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.2510130905","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2510130905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T12:34:08Z","timestamp":1698064448000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2510130905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,12]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1992,12]]}},"alternative-id":["10.1002\/bdd.2510130905"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2510130905","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,12]]}}}